Skip to main
VNRX

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd is expanding its total addressable market through the development of a feline assay, which is expected to significantly enhance revenue opportunities, particularly in the rapidly growing sector of feline oncology. The company has made noteworthy strides in commercialization, evidenced by the successful launch of its CE-Marked Nu.Q NETs automated assays in over 20 hospitals across multiple countries, and partnerships with industry leaders like Werfen and Hologic that are expected to bolster its human diagnostics strategy. Additionally, advancements in scientific validation and a strong market presence, particularly with the Nu.Q Vet Cancer Test, position VolitionRX favorably for sustained growth and recurring revenue generation across its diagnostic platforms.

Bears say

VolitionRX Ltd faces heightened dilution risk, which has negatively impacted its financial outlook as reflected in a reduced price target forecast from $5.00 to $3.00. This dilution risk may arise from potential additional capital raising efforts needed to fund operations and development within the highly competitive field of diagnostics. Consequently, this scenario contributes to uncertainty regarding shareholder value and overall market confidence in the company's growth prospects.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.